DRD2 and neoplasm: D2R agonists have also been found to abrogate lung tumor progression in syngeneic (Lewis Lung Carcinoma; LLC) and human xenograft (A549) orthotopic murine models and reduce tumor-infiltrating myeloid-derived suppressor cells (205).